A drug-based delivery carrier that can release drugs such as anti-inflammatory agents on demand in response to inflammation has been developed. This has been achieved by scientists from Harvard-MIT Division of Health Science and Technology (HST) at Brigham and Women's Hospital. The new self-assembling hydrogel drug delivery system is biocompatible, efficient at drug release and easy to manipulate. These structures can deliver clinically approved drugs in high concentrations without requiring carriers for the drug without generating toxic components which is a common problem with hydrogel systems until now. Enzyme triggered gel degradation is the key strength, which plays a major role in developing these delivery vehicles from drugs-based hydrogels.